On Nov. 16, The Ohio State University signed an agreement with Nanobio Delivery Pharmaceutical Co.,Ltd. for $1.4 million to support the set-up of a Center for RNA Nanotechnology and Nanomedicine
for cancer research. The director of the new center is Peixuan Guo,PhD,
a professor in the College of Pharmacy who also holds the Sylvan Frank Endowed Chair of Drug Delivery and is a member of the Translational Therapeutics Program at the OSUCCC – James. Guo, whose major research interest is applying RNA nanotechnology to cancer therapy, says 15 people attended the signature ceremony. Shown above (seated from left) are Guo; Haibo Hu, CEO of Nanobio Delivery Pharmaceutical Co. Ltd.; Cynthia Carnes, PharmD, PhD
, associate dean of the College of Pharmacy; and (standing from left) Kristy Baker
, director of the Office for Business & Industry Contracts at Ohio State; Matt McNair
, vice president of economic & corporate engagement at Ohio State; David Mess
, senior technology licensing manager – life science at Ohio State; and Maggie Merry
, chief administrative officer for the College of Pharmacy.